BVM Capital, LLC was a venture capital and private equity firm based in Bossier City, Louisiana, with additional offices in New York and New Orleans. Established in 2003, the firm specialized in early and expansion stage investments, primarily focusing on life sciences, healthcare, technology, biotechnology, and pharmaceuticals. BVM Capital aimed to support companies in the Southeast, particularly in Louisiana, by investing equity ranging from $0.1 million to $3 million. The firm typically sought a board seat in its portfolio companies and generally held investments for three to seven years, looking to exit through mergers, acquisitions, or initial public offerings. BVM Capital is no longer operational.
K94 Discoveries, Inc. operates as a biotechnology company and develops anticancer drugs based on discoveries by scientists at LSU’s Pennington Biomedical Research Institute and Feist Weiller Cancer Center. The company is based in the United States.
NuMe Health is a biotechnology company focused on medical foods for the special dietary requirements associated with major chronic diseases including: cancer, obesity, and diabetes.
NuMe Health is a biotechnology company focused on medical foods for the special dietary requirements associated with major chronic diseases including: cancer, obesity, and diabetes.
CaloSyn Pharma, Inc. is a biopharmaceutical company focused on developing intra-articular therapeutics specifically for osteoarthritis (OA), a condition affecting over 27 million people in the United States and more than 100 million globally. Founded in 2007 and headquartered in Boston, Massachusetts, with additional offices in Shreveport, Louisiana, and Atlanta, Georgia, the company is advancing a novel approach to OA treatment through the use of calcium channel blockers, drugs traditionally employed in heart and vascular disease management. By leveraging new insights into the mechanisms of these drugs and the processes underlying joint damage and pain in osteoarthritis, CaloSyn Pharma aims to reformulate and repurpose these medications for direct injection into affected joints. The company is currently conducting a Phase II clinical trial in the United States to evaluate the efficacy of its therapeutic approach.